Atezolizumab and durvalumab, anti-PD-L1 monoclonal antibodies, were approved as a first-line treatment in combination with chemotherapy for small cell lung cancer (SCLC) [5,6,7]. The gene discussed is CD274; the disease is small cell lung carcinoma.